| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -39,993 | -23,677 |
| Credit loss - related party accounts receivable | 0 | 0 |
| Stock-based compensation expense | 2,367 | 867 |
| Non-cash lease expense | 296 | 213 |
| Unrealized (gain) loss on short-term investments | 14 | -22 |
| Amortization of discount on short-term investments | 1,073 | 701 |
| Depreciation expense | 26 | 16 |
| Prepaid expenses and other assets | 5,591 | 4,278 |
| Accounts payable | 2,611 | 3,223 |
| Accrued liabilities | 4,243 | 3,217 |
| Operating lease liability | -234 | -134 |
| Net cash used in operating activities | -37,362 | -21,232 |
| Purchases of short-term investments | 124,651 | 124,651 |
| Maturities/sales of short-term investments | 50,777 | 21,527 |
| Purchases of property and equipment | 95 | 91 |
| Net cash used in investing activities | -73,969 | -103,215 |
| Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts | 91,075 | 91,075 |
| Financing costs paid in connection with issuance | 2,387 | 2,387 |
| Proceeds from sale and issuance of series c convertible preferred stock | 0 | 0 |
| Financing costs paid in connection with issuance of series c convertible preferred stock | 0 | 0 |
| Proceeds from exercises of common stock options | 287 | 116 |
| Net cash provided by financing activities | 88,975 | 88,804 |
| Net (decrease) increase in cash and cash equivalents | -22,356 | -35,643 |
| Cash and cash equivalents at beginning of period | 61,641 | - |
| Cash and cash equivalents at end of period | 39,285 | - |
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)